Detecting Significant Prostate Cancer Based on Molecular Alterations Associated With Cancer in Non-neoplastic Prostate Tissue


About this study

The goal of this study is to improve detection of prostate cancers that require treatment. Achieving the aims of this research will lead to better care and reduced anxiety for patients suspected of aggressive prostate cancer.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

Patients who undergo cystoprostatectomy operations and have their prostates resected because of bladder cancer 

  • Normal Prostate Tissues
    • These will be from men free of prostate cancer whose prostate are removed in a cystoprostatectomy operation because of bladder cancer.
    • Benign areas of frozen prostate tissues from men who had radical prostatectomy

Exclusion Criteria:

  • Patients with incidental prostate cancer, urothelial carcinomas of the prostate/prostate ducts/prostate urethra, abnormal DRE, or elevated PSA ( > 2ng/ml) will be excluded.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Farhad Kosari, Ph.D.

Closed for enrollment

Contact information:

Debra Head C.C.R.C.


More information


Publications are currently not available

Mayo Clinic Footer